Nemus Bioscience (OTCMKTS:NMUS) and Prestige Consumer Healthcare (NYSE:PBH) Financial Analysis

Prestige Consumer Healthcare (NYSE:PBH) and Nemus Bioscience (OTCMKTS:NMUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Prestige Consumer Healthcare and Nemus Bioscience, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	0	2	2	0	2.50
Nemus Bioscience	0	0	0	0	0.00

Prestige Consumer Healthcare currently has a consensus price target of $85.25, suggesting a potential upside of 7.41%. Given Prestige Consumer Healthcare’s stronger consensus rating and higher probable upside, research analysts plainly believe Prestige Consumer Healthcare is more favorable than Nemus Bioscience.

Profitability

This table compares Prestige Consumer Healthcare and Nemus Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	18.54%	12.23%	6.14%
Nemus Bioscience	N/A	N/A	-924.42%

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Nemus Bioscience has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Valuation and Earnings

This table compares Prestige Consumer Healthcare and Nemus Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.11 billion	3.53	$209.34 million	$4.11	19.31
Nemus Bioscience	N/A	N/A	-$19.19 million	N/A	N/A

Prestige Consumer Healthcare has higher revenue and earnings than Nemus Bioscience.

Institutional and Insider Ownership

99.9% of Prestige Consumer Healthcare shares are owned by institutional investors. 1.6% of Prestige Consumer Healthcare shares are owned by company insiders. Comparatively, 2.7% of Nemus Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Nemus Bioscience on 10 of the 11 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About Nemus Bioscience

Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.